Sell RIM!: Against ...
Health Care: Drugs
Cytokinetics Inc. (CYTK: NASDAQ)
$0.88 -0.02 | -2.17%
06/04/12 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.90 |
| 52 Week High | 1.45 |
| 52 Week Low | 0.85 |
| Avg. Daily Vol. (Mil) | 0.21 |
| Beta (3 year) | 1.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 69.76 |
| Shares Out (Mil) | 77.51 |
| Float (Mil) | 72.93 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 9.70 |
| Current Ratio | 10.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 13.79 |
| Price/Book | 1.66 |
| Price/Cash Flow | -1.50 |
| Per Share Data | |
| Earnings | -0.68 |
| Sales | 0.07 |
| Book Value | 0.54 |
| Cash Flow | -0.62 |
| Business Summary | |
|---|---|
| Cytokinetics, Inc.is a clinical-stage biopharmaceutical company, which focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. | |
| General Information | |
| 280 East Grand Avenue
South San Francisc, CA 94080 |
|
| www.cytokinetics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 79 | |
| CEO: Robert I. Blum | |
| Short Interest | |
| Current Month (Mil) | 0.54 |
| Previous Month (Mil) | 0.52 |
| Short Interest Ratio (Days) | 2.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -99.00 |
| Return on Investments | -109.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CYTK
- Portfolio NameUser Type
- Contributor$5 Stocks That Analysts Exp...
- UserBlue OAK
- UserDaveofDuke1111
- UserASCO 2010 Part 2
- ContributorBarron's Insider Purchases ...
- UserASCO 2009 Nymph's Watch List.
- UserHot Biotech Stocks II
- UserLet's Go Channeling
- UserDizziMage's Port
- Usermileslb Fidelity IRA
Latest CYTK Headlines from TheStreet
- Cytokinetics CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 11:10 pm
- $5 Stocks That Analysts Expect to Double 08.02.10 | 06:08 am
- Cytokinetics Inc. Q2 2010 Earnings Call Transcript 07.29.10 | 03:07 am
- Cytokinetics Ends Cancer Deal With GlaxoSmithKline 12.09.09 | 04:12 pm
- Movers Roundup: Manitowoc, Symantec 10.29.09 | 02:10 pm
- Cytokinetics Shares Fall On Drug Development Delay 10.29.09 | 12:10 pm
- Harmonic, SkyPeople: Midday Volume Plays 10.29.09 | 12:10 pm
- High Times
09.29.09 | 10:09 am - Cytokinetics: Pump Up The Volume 09.25.09 | 03:09 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
Press Releases for CYTK
Partner Headlines for CYTK
- Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT - Benzinga 11.01.11 | 04:11 pm
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- Cytokinetics Up 9% (CYTK) - Benzinga 04.12.11 | 09:04 am
- Cytokinetics: Most Recent Victim of Unjustified Biotech Sell-Off - Seeking Alpha 12.19.10 | 07:12 am
- UPDATE 1-Cytokinetics' Lou Gehrig's drug gets orphan status - Reuters 03.10.10 | 09:03 am
